CDKN2B-AS1 and breast carcinoma: We confirmed our experimental results by performing an in-silico analysis of mRNA expression levels in the TCGA series (RNA sequencing data from https://www.cbioportal.org), which showed positive correlation between ANRIL and p14-ARF and p16-CDKN2A (p < 0.0001), and between ANRIL and p15-CDKN2B (p < 0.0001) in both breast carcinomas and prostate carcinomas (Supplementary Table S3).